Chemomab Therapeutics (NASDAQ:CMMB) Shares Up 0.4% – Should You Buy?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB)’s share price shot up 0.4% during trading on Friday . The stock traded as high as $1.39 and last traded at $1.37. 133,868 shares changed hands during trading, a decline of 37% from the average session volume of 211,574 shares. The stock had previously closed at $1.36.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CMMB. Oppenheimer lowered their price target on shares of Chemomab Therapeutics from $11.00 to $10.00 and set an “outperform” rating for the company in a research report on Friday, May 16th. Maxim Group upped their price target on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th.

Chemomab Therapeutics Price Performance

The firm has a market cap of $19.60 million, a price-to-earnings ratio of -1.37 and a beta of 0.55. The firm’s fifty day moving average is $1.20 and its two-hundred day moving average is $1.59.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.06. On average, equities analysts forecast that Chemomab Therapeutics Ltd. will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Virtu Financial LLC acquired a new position in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,445 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.10% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).